¼¼°èÀÇ µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀå
Freeze and Thaw Systems
»óǰÄÚµå : 1757593
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 368 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,009,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,027,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 5¾ï 1,800¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 8,180¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â¿¡´Â 5¾ï 1,800¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 5.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ µ¿°á À¶ÇØ ¸ðµâ½Ä Ç÷§ÆûÀº CAGR 6.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 2¾ï 5,230¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦¾î ¼Óµµ è¹ö ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 400¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 1¾ï 400¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 460¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.4%¿Í 5.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹ÙÀÌ¿ÀÀǾàǰ ¹× ÀÓ»ó ¿öÅ©Ç÷ο쿡¼­ µ¿°á À¶ÇØ ½Ã½ºÅÛÀÌ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

µ¿°á À¶ÇØ ½Ã½ºÅÛÀº ¹é½Å, ¸ð³ëŬ·Î³Î Ç×ü, Ç÷Àå, È¿¼Ò, ¼¼Æ÷¹è¾ç µî ¿Âµµ¿¡ ¹Î°¨ÇÑ »ý¹°ÇÐÀû ¹°ÁúÀÇ º¸Á¸ ¹× ¾ÈÁ¤È­¿¡ »ç¿ëµÇ´Â Áß¿äÇÑ ±â¼úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ´ë·®ÀÇ »ý¹°Á¦Á¦ÀÇ µ¿°á ¹× ÇØµ¿À» Á¦¾îÇϰí Á¦Á¶, º¸°ü, ¿î¼ÛÀÇ »çÀÌŬÀ» ÅëÇØ ±¸Á¶Àû ¹«°á¼º, È¿´É ¹× ¹«±Õ¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ±âÁ¸ÀÇ ¼öµ¿ ³Ãµ¿ ¹æ½Ä°ú ´Þ¸®, ÃֽŠ½Ã½ºÅÛÀº GMP ¹× ÄݵåüÀÎ ¹°·ù ¿ä°ÇÀ» ÁؼöÇÏ´Â ÀÚµ¿È­µÇ°í È®Àå °¡´ÉÇÏ¸ç ¹Ýº¹ °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

»ý¹°Á¦Á¦, À¯ÀüÀÚ Ä¡·á, ¸ÂÃãÇü ÀǷḦ Áß½ÉÀ¸·Î ÇÑ ¼¼°è »ý¸í°úÇÐ »ê¾÷ÀÌ È®´ëµÊ¿¡ µû¶ó ³Ãµ¿ ¹× ÇØµ¿ Áֱ⠵¿¾È Á¦Ç° ¿­È­¸¦ ÃÖ¼ÒÈ­ÇØ¾ß ÇÑ´Ù´Â ¾Ð¹ÚÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. ºÎÀûÀýÇÑ µ¿°áÀº ´Ü¹éÁú°ú ¼¼Æ÷¸¦ ¼Õ»ó½ÃŰ´Â ¾óÀ½ °áÁ¤ÀÇ Çü¼ºÀ¸·Î À̾îÁö°í, ºÒ±ÕÀÏÇÑ ÇØµ¿Àº ³óµµ ±¸¹è¿Í º¯¼ºÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. µ¿°á À¶ÇØ ½Ã½ºÅÛÀº ¿­ ±ÕÀϼºÀ» À¯ÁöÇϰí, ó¸® ½Ã°£À» ´ÜÃàÇϰí, ¹èÄ¡ ¼Õ½ÇÀ» ÁÙÀÌ´Â Á¤¹Ð ¿£Áö´Ï¾î¸µ ¼Ö·ç¼ÇÀ¸·Î ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ¿© Á¦¾à, »ý¸í°øÇÐ ¹× ÀÓ»ó ºÐ¾ß¿¡¼­ ÇʼöÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô ½Ã½ºÅÛÀÇ Á¤È®¼º°ú È®À强À» ³ôÀ̴°¡?

±â¼úÀÇ ¹ßÀüÀº ³Ãµ¿ ¹× ÇØµ¿ °øÁ¤ÀÇ È¿À²¼º, ÃßÀû¼º ¹× È®À强À» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. ÇöÀç ½Ã½ºÅÛÀº ÇÁ·Î±×·¥ °¡´ÉÇÑ ¿Âµµ Á¦¾î, Ç÷¹ÀÌÆ® ±â¹Ý ¶Ç´Â ½© ±â¹Ý Á¢ÃË ³Ãµ¿, ¿ë±â Àüü¿¡ °ÉÃÄ ±ÕÀÏÇÑ ¿­±³È¯À» º¸ÀåÇÏ´Â À¯Ã¼ ÀçŶ ½Ã½ºÅÛÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÀÏȸ¿ë ¹é, º´, ½ºÅ×Àθ®½º°­ ¿ë±â µî ´Ù¾çÇÑ ÇüÅ·ΠÁ¦°øµÇ¸ç, Á¾Á¾ ¾÷½ºÆ®¸² ¹× ÇÏ·ù ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¿ëµµÀÇ ÀÚµ¿ »ý»ê ¶óÀο¡ ÅëÇյǾî ÀÖ½À´Ï´Ù.

ÃֽŠ½Ã½ºÅÛ¿¡´Â ¼¾¼­, µ¥ÀÌÅÍ ·Î°Å, PLC ±â¹Ý ÄÁÆ®·Ñ·¯°¡ ³»ÀåµÇ¾î ÀÖÀ¸¸ç, ÄÚ¾î ¿Âµµ, ÇÁ¸®Áî ÇÁ·ÐÆ® ÁøÇà, Àüü »çÀÌŬ Áö¼Ó ½Ã°£ µîÀ» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶ ½ÇÇà ½Ã½ºÅÛ(MES) ¹× ÀüÀÚ ¹èÄ¡ ±â·Ï(EBR)°úÀÇ ÅëÇÕÀ» ÅëÇØ 21 CFR Part 11 ¹× ±âŸ ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ¸ðµâ½Ä ¹× ´ÙǰÁ¾ ¼³ºñ¿¡¼­ ÀÏȸ¿ë ±â¼úÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó À¯¿¬Çϰí ÀÏȸ¿ë¿¡ ÀûÇÕÇϸç Ŭ¸°·ë¿¡ ÀûÇÕÇÑ ³Ãµ¿ ¹× ÇØµ¿ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±À¸·Î ´ë±Ô¸ð »ý¹°Á¦Á¦ Á¦Á¶¿¡¼­ ¹èÄ¡ ȸÀü ¼Óµµ¸¦ ³ôÀ̰í, ¿À¿° À§ÇèÀ» ÁÙÀ̸ç, È®À强À» Çâ»ó½Ãų ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

µ¿°á À¶ÇØ ½Ã½ºÅÛ µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ´Â »ê¾÷ ¹× ¿ëµµ´Â?

µ¿°á À¶ÇØ ½Ã½ºÅÛÀº Áß¿äÇÑ Áß°£Ã¼ ¹× ¿Ï¼ºµÈ »ý¹°Á¦Á¦ÀÇ Ãë±ÞÀ» Áö¿øÇÏ´Â ¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ß¿¡¼­ °¡Àå ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼öŹÁ¦Á¶¾÷ü(CMO), ¹é½Å Á¦Á¶¾÷ü, ¼¼Æ÷Ä¡·áÁ¦ °³¹ß¾÷ü, Ç÷ÀåºÐȹÁ¦Á¦ ¾÷üµéÀº ±úÁö±â ½¬¿î »ý¹°Á¦Á¦ÀÇ ¾ÈÀüÇÏ°í ¹Ýº¹ °¡´ÉÇÑ Ãë±ÞÀ» º¸ÀåÇϱâ À§ÇØ ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, mRNA ±â¹Ý ¹é½Å, ´Ü¹éÁú Ä¡·áÁ¦, À¯ÀüÀÚ ÆíÁý ½Ã¾àÀÇ Àü ¼¼°è »ý»êÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ´Â ±ØÀú¿Â °øÁ¤ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÀÓ»ó ½ÇÇè½Ç, Ç÷¾×ÀºÇà, Áٱ⼼Æ÷ º¸°ü½Ã¼³Àº Áø´Ü, À̽Ä, Ä¡·á ÀÌ¿ë »ç·Ê¿¡¼­ ½Ã·áÀÇ ¹«°á¼ºÀ» °ü¸®Çϱâ À§ÇØ µ¿°á-ÇØµ¿ Á¦¾î Ç÷§ÆûÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ½Äǰ, ³ó¾÷, È­Àåǰ »ê¾÷¿¡¼­´Â °íºÎ°¡°¡Ä¡ ¿ø·á º¸°ü, Á¶Á÷ ¹è¾ç °ü¸®, R&D ¿öÅ©Ç÷ο쿡 ¼Ò±Ô¸ð ½Ã½ºÅÛÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ¹°·ù¿¡¼­ °ø±Þ¸Á ¾ÈÁ¤¼ºÀÇ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¦3ÀÚ ¹°·ù ÇÁ·Î¹ÙÀÌ´õµéÀÌ ÄݵåüÀÎ ¿î¼Û ÀÎÇÁ¶ó¿¡ ÅëÇÕ ³Ãµ¿ ¹× ÇØµ¿ ½Ã½ºÅÛÀ» µµÀÔÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

µ¿°á À¶ÇØ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¹ÙÀÌ¿À Á¦Á¶ÀÇ È®´ë, ǰÁú º¸Áõ¿¡ ´ëÇÑ ¼ö¿ä, ±â¼ú ¹ßÀü°ú °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¸ð³ëŬ·Î³Î Ç×ü, ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦, ¹é½Å µî °íµµ·Î Á¦¾îµÇ°í °ËÁõµÈ ¿­Ã³¸® ȯ°æÀ» ÇÊ¿ä·Î ÇÏ´Â »ý¹°Á¦Á¦ÀÇ »ý»êÀÌ ±ÞÁõÇϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷ÀÌ ¿¬¼ÓÀûÀÌ°í ¸ðµâÈ­µÈ Á¦Á¶·Î ÀüȯÇÔ¿¡ µû¶ó ¹èÄ¡ °£ Àϰü¼ºÀ» À¯ÁöÇϸ鼭 ´ë·® »ý»ê¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â µ¿°á À¶ÇØ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¦Ç° ¹«°á¼º ¹× ÄݵåüÀÎ °ËÁõ¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã°¡ °­È­µÇ¸é¼­ ±â¾÷ÀÌ ÀÚµ¿È­µÈ µ¥ÀÌÅÍ ÃßÀû ½Ã½ºÅÛÀ» µµÀÔÇØ¾ß ÇÏ´Â °Íµµ ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ½ºÅ×Àθ®½º°­¿¡¼­ ÀÏȸ¿ë ±â¼ú·ÎÀÇ ÀüȯÀº ÀÏȸ¿ë, ¹«±Õ, °øÁ¤ ÀûÇÕ¼ºÀ» Á¦°øÇÏ´Â µ¿°á À¶ÇØ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À Á¦¾à ½Ã¼³µéÀÌ ½ÅÈï ½ÃÀåÀ¸·Î ÁøÃâÇÔ¿¡ µû¶ó ÀÎÇÁ¶ó ÅõÀÚ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ°í ¹Ýº¹ °¡´ÉÇÑ µ¿°á/ÇØµ¿ °øÁ¤¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î µ¿°á/ÇØµ¿ ½Ã½ºÅÛÀº ¹Ì·¡ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹× ÀÓ»ó Á¦Ç° °ü¸®ÀÇ ±âº» ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(µ¿°á À¶ÇØ ¸ðµâ·¯ Ç÷§Æû, ÄÁÆ®·Ñ ·¹ÀÌÆ® è¹ö, ÀÏȸ¿ë ¹é, ±âŸ Á¦Ç°), ¿ëµµ(¿¬±¸°³¹ß ¿ëµµ, ÀüÀÓ»ó¡¤ÀÓ»ó ¿ëµµ, »ó¾÷ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Çмú¡¤¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, CRO¡¤CMO ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 32»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è µµ¸ÞÀÎ Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Freeze and Thaw Systems Market to Reach US$518.0 Million by 2030

The global market for Freeze and Thaw Systems estimated at US$381.8 Million in the year 2024, is expected to reach US$518.0 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Freeze-Thaw Modular Platforms, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$252.3 Million by the end of the analysis period. Growth in the Controlled Rate Chambers segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$104.0 Million While China is Forecast to Grow at 8.5% CAGR

The Freeze and Thaw Systems market in the U.S. is estimated at US$104.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.6 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Freeze and Thaw Systems Market - Key Trends & Drivers Summarized

Why Are Freeze and Thaw Systems Becoming Essential in Biopharmaceutical and Clinical Workflows?

Freeze and thaw systems are critical technologies used to preserve and stabilize temperature-sensitive biological materials, such as vaccines, monoclonal antibodies, plasma, enzymes, and cell cultures. These systems support the controlled freezing and thawing of large-volume biologics to ensure their structural integrity, potency, and sterility throughout manufacturing, storage, and transportation cycles. In contrast to conventional manual freezing approaches, modern systems provide automated, scalable, and repeatable solutions that comply with good manufacturing practices (GMP) and cold chain logistics requirements.

As the global life sciences industry expands-driven by biologics, gene therapy, and personalized medicine-there is growing pressure to minimize product degradation during freeze/thaw cycles. Improper freezing can lead to ice crystal formation that damages proteins or cells, while uneven thawing can result in concentration gradients or denaturation. Freeze and thaw systems address these challenges with precision-engineered solutions that maintain thermal uniformity, reduce processing time, and mitigate batch loss, making them indispensable across pharmaceutical, biotechnology, and clinical sectors.

How Are Technology Innovations Enhancing System Precision and Scalability?

Technological advancements are significantly improving the efficiency, traceability, and scalability of freeze and thaw processes. Current systems utilize programmable temperature control, plate-based or shell-based contact freezing, and fluid jacket systems to ensure uniform heat exchange across containers. These systems are capable of handling various formats, including single-use bags, bottles, and stainless-steel containers, and they are often integrated into automated production lines for upstream and downstream bioprocessing applications.

Modern systems are embedded with sensors, data loggers, and PLC-based controllers that allow real-time monitoring of core temperature, freeze front progression, and total cycle duration. Integration with manufacturing execution systems (MES) and electronic batch records (EBR) supports compliance with 21 CFR Part 11 and other regulatory standards. The growing use of single-use technologies, particularly in modular and multi-product facilities, is spurring demand for freeze and thaw systems that are flexible, disposable-compatible, and cleanroom-suitable. These improvements are enabling faster batch turnover, reduced contamination risk, and better scalability for large-scale biologics manufacturing.

Which Industries and Applications Are Accelerating Adoption of Freeze and Thaw Systems?

Freeze and thaw systems are most extensively used in the biopharmaceutical sector, where they support the handling of critical intermediates and finished biologic drugs. Contract manufacturing organizations (CMOs), vaccine producers, cell therapy developers, and plasma fractionation companies rely on these systems to ensure the safe and repeatable handling of fragile biologics. With the increasing global production of mRNA-based vaccines, protein therapeutics, and gene-editing reagents, demand for reliable cryogenic process systems is expanding rapidly.

Additionally, clinical laboratories, blood banks, and stem cell repositories utilize controlled freeze and thaw platforms to manage specimen integrity in diagnostic, transplantation, and therapeutic use cases. In the food, agriculture, and cosmetics industries, smaller-scale systems are used for high-value ingredient storage, tissue culture management, and R&D workflows. The growing importance of supply chain stability in biopharma logistics is also driving third-party logistics providers to adopt integrated freeze/thaw systems within cold chain transport infrastructure.

What Are the Primary Drivers Fueling Growth in the Freeze and Thaw Systems Market?

The growth in the freeze and thaw systems market is driven by several factors related to biomanufacturing expansion, quality assurance demands, and technology evolution. One of the main drivers is the surge in biologics production-particularly monoclonal antibodies, cell-based therapies, and vaccines-which require highly controlled and validated thermal processing environments. As biopharma companies shift toward continuous and modular manufacturing, there is rising adoption of freeze/thaw systems that can handle bulk volumes while maintaining consistency across batches.

Another key growth factor is the increasing regulatory scrutiny surrounding product integrity and cold chain validation, which is prompting firms to adopt automated, data-traceable systems. The shift from stainless steel to single-use technologies is also accelerating demand for freeze and thaw systems that offer disposability, sterility, and process compatibility. Furthermore, as biopharma facilities expand into emerging markets, the need for reliable and repeatable freeze/thaw processes is growing alongside infrastructure investments. These combined drivers are positioning freeze and thaw systems as foundational elements in the future of bioprocessing and clinical product management.

SCOPE OF STUDY:

The report analyzes the Freeze and Thaw Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Freeze-Thaw Modular Platforms, Controlled Rate Chambers, Single-Use Bags, Other Products); Application (R&D Application, Pre-Clinical & Clinical Application, Commercial Application); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, CROs & CMOs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â